(Reuters) - ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study.
ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year.
Kadcyla, approved in 2013 for the treatment of late-stage breast cancer, was being tested as a second-line treatment for gastric cancer in the late-stage study.
The drug raked in revenue of about $580.3 million this year.
Kadcyla carries a cell-killing payload directly into cancer cells, causing fewer cases of common chemotherapy side effects like hair loss.
Detailed findings from the trial will be reported at a future medical conference, the company said.
Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva